-
Full Article (HTML) (26) -
Full Article (PDF) (7)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4557)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2015 (publication date) through Jul 14, 2020
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Number | Cited Articles |
| 1 |
Vincenzo B. Polsinelli, Lara Marteau, Sanjiv J. Shah. The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. Current Opinion in Supportive and Palliative Care 2019; 13(1): 24 doi: 10.1097/SPC.0000000000000414
|
| 2 |
Y.-L. Wang, H.-J. He, X.-X. Xiao, Y. Lin, B.-Q. Wang, S.-L. Zhu, G.-S. Yang, S.-S. Huang, Q.-G. Yang. Letter: rifaximin is more than helping hepatic encephalopathy-it also saves lives. Alimentary Pharmacology & Therapeutics 2017; 46(11-12): 1122 doi: 10.1111/apt.14353
|
| 3 |
Eric G Meissner. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. Clinical Infectious Diseases 2018; 67(6): 878 doi: 10.1093/cid/ciy208
|
| 4 |
Alberto Nicoletti, Francesca Romana Ponziani, Marco Biolato, Venanzio Valenza, Giuseppe Marrone, Gabriele Sganga, Antonio Gasbarrini, Luca Miele, Antonio Grieco. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World Journal of Gastroenterology 2019; 25(33): 4814-4834 doi: 10.3748/wjg.v25.i33.4814
|
| 5 |
Jasmohan S. Bajaj, Giovanni Barbara, Herbert L. DuPont, F. Mearin, Antonio Gasbarrini, Jan Tack. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Digestive and Liver Disease 2018; 50(8): 741 doi: 10.1016/j.dld.2018.04.020
|
| 6 |
Vincenzo B. Polsinelli, Arjun Sinha, Sanjiv J. Shah. Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Current Heart Failure Reports 2017; 14(6): 519 doi: 10.1007/s11897-017-0370-8
|
| 7 |
Caio Pupin Rosa, Gustavo Andrade Brancaglion, Tatimara M. Miyauchi-Tavares, Patrícia Paiva Corsetti, Leonardo Augusto de Almeida. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussions. Life Sciences 2018; 207: 480 doi: 10.1016/j.lfs.2018.06.030
|
| 8 |
Edford Sinkala, Michael Vinikoor, Kanekwa Zyambo, Ellen Besa, Bright Nsokolo, Paul Kelly. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.
The American Journal of Tropical Medicine and Hygiene 2020; 102(4): 832 doi: 10.4269/ajtmh.19-0452
|
| 9 |
Francesca Romana Ponziani, Venanzio Valenza, Erida Nure, Giuseppe Bianco, Giuseppe Marrone, Antonio Grieco, Maurizio Pompili, Antonio Gasbarrini, Salvatore Agnes, Gabriele Sganga, Gianfranco D. Alpini. Effect of liver transplantation on intestinal permeability and correlation with infection episodes. PLOS ONE 2020; 15(6): e0235359 doi: 10.1371/journal.pone.0235359
|
| 10 |
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
|
| 11 |
Beatrice Campanella, Massimo Onor, Tommaso Lomonaco, Edoardo Benedetti, Emilia Bramanti. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Analytical and Bioanalytical Chemistry 2019; 411(28): 7551 doi: 10.1007/s00216-019-02158-6
|
| 12 |
S. Mouri, C. Bouzbib, H. El Mourabit, A. Schaefer, F. Imbert-Bismut, D. Galanaud, S. Tripon, M. Mallet, M. Rudler, C. Housset, D. Thabut, N. Weiss. L’encéphalopathie hépatique, du diagnostic au traitement en 2016. Réanimation 2016; doi: 10.1007/s13546-016-1223-2
|
| 13 |
Francesca Romana Ponziani, Maria Assunta Zocco, Lucia Cerrito, Antonio Gasbarrini, Maurizio Pompili. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Review of Gastroenterology & Hepatology 2018; 12(7): 641 doi: 10.1080/17474124.2018.1481747
|
| 14 |
Francesca Romana Ponziani, Alberto Nicoletti, Antonio Gasbarrini, Maurizio Pompili. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2019; 11: 175883591984818 doi: 10.1177/1758835919848184
|
| 15 |
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
|
| 16 |
Alec B. Rezigh, Erin Armenia, Ting Li, Irene Soesilo. Rifaximin as a rare cause of rhabdomyolysis in cirrhosis. Clinical Case Reports 2018; 6(7): 1296 doi: 10.1002/ccr3.1583
|
| 17 |
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
|
| 18 |
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018; 27(6): 543 doi: 10.1080/13543784.2018.1483333
|
| 19 |
Ying Yuan, Xiaomei Wang, Xiangyi Xu, Yu Liu, Cancan Li, Meng Yang, Yiqing Yang, Zhenkun Ma. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. ACS Infectious Diseases 2020; 6(5): 820 doi: 10.1021/acsinfecdis.9b00374
|
| 20 |
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut and Liver 2017; 11(5): 702 doi: 10.5009/gnl16478
|
| 21 |
Russell Rosenblatt, Amit Mehta, Shirley Cohen‐Mekelburg, Nicole Shen, David Snell, Catherine Lucero, Arun Jesudian, Brett Fortune, Carl V. Crawford, Sonal Kumar.
The rise of
Clostridioides difficile
infections and fall of associated mortality in hospitalized advanced cirrhotics
. Liver International 2019; 39(7): 1263 doi: 10.1111/liv.14077
|
| 22 |
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa, Kiwamu Okita. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatology Research 2018; 48(6): 411 doi: 10.1111/hepr.13045
|
| 23 |
Simona Iacob, Diana Gabriela Iacob. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.01676
|
| 24 |
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice. Frontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00044
|
| 25 |
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035
|